19-Nor safely and effectively reduces PTH levels in hemodialysis patients.
ASN 30th Annual Meeting, San Antonio
J Am Soc Nephrol (Sep) 8:576A 1997
As with other new vitamin D metabolites 19-nor,1-alpha,25 hydroxyvitamin D2 inhibits PTH without excessively worsening calcium and phosphate levels. Given intravenously to 40 patients this agent reduced PTH by 48% (the goal was to suppress PTH by 30%) from 783 to 404 pg/ml. In contrast 38 control subjects showed no PTH reduction (PTH averaged 745 at baseline and 676 at study end). None of the 19-Nor patients developed hypercalcemia prior to achieving goal PTH. There were similar rates of side effects in treated and control subjects, 68% and 79 %, respectively, mostly hyperphosphatemia.
Comment: Thus, PTH was reduced with much fewer than expected episodes of calcium or phosphate elevation, a fascinating and provocative finding. (Donald Sherrard, M.D., University of Washington)
To go back use the BACK button on your browser. Otherwise click on the desired link to this article below:
ASN 30th Annual Meeting, San Antonio
CRF by problem area : Bone disease/aluminum